​

Tarsus Pharmaceuticals (TARS) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Tarsus Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$17.45M

Latest Revenue (Q)

$48.12M

Main Segment (Y)

Product

Tarsus Pharmaceuticals Revenue by Period

Tarsus Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31$17.45M-32.42%
2022-12-31$25.82M-54.73%
2021-12-31$57.03M100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31--

Tarsus Pharmaceuticals generated $17.45M in revenue during NA 2023, up -32.42% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Tarsus Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-09-30$48.12M17.90%
2024-06-30$40.81M47.80%
2024-03-31$27.61M111.18%
2023-12-31$13.08M598.88%
2023-09-30$1.87M-87.75%
2023-06-30$15.28M511.08%
2023-03-31$2.50M-75.00%
2022-12-31$10.00M100.00%
2022-09-30--100.00%
2022-06-30$15.28M2734.32%
2022-03-31$539.00K59.47%
2021-12-31$338.00K-72.74%
2021-09-30$1.24M-94.37%
2021-06-30$22.02M-34.14%
2021-03-31$33.43M100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2018-06-30-100.00%
2018-03-31--

Tarsus Pharmaceuticals generated $48.12M in revenue during Q3 2024, up 17.90% compared to the previous quarter, and up 314.97% compared to the same period a year ago.

Tarsus Pharmaceuticals Revenue Breakdown

Tarsus Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21
License Fees and Collaboration$2.72M$955.00K$2.08M
Product$14.73M--
Collaboration Revenue-$1.92M$3.96M
License and Service-$23.89M$53.07M

Tarsus Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (84.42%), and License Fees and Collaboration (15.58%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Sep 23Mar 23Dec 22Jun 22Mar 22Sep 21Jun 21Mar 21
Product$48.12M$24.72M$13.08M$1.65M-------
License And Collaboration-$2.89M$218.00K$2.50M$522.00K$33.00K$65.00K$737.00K$1.30M--
License and Service-----$10.00M$13.89M-$708.00K$19.05M$33.31M
Collaboration------$1.38M$539.00K$532.00K$2.97M$121.00K

Tarsus Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (100.00%).

Tarsus Pharmaceuticals Revenue Breakdown by Country

Quarterly Revenue by Country

CountryMar 23Dec 22Jun 22Mar 22Sep 21Jun 21Mar 21
License And Collaboration$2.50M$522.00K$33.00K$65.00K$737.00K$1.30M-
License and Service-$10.00M$13.89M-$708.00K$19.05M$33.31M
Collaboration--$1.38M$539.00K$532.00K$2.97M$121.00K

Tarsus Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 23: License And Collaboration (100.00%).

Tarsus Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
TVTXTravere Therapeutics$145.24M$62.90M
TRDAEntrada Therapeutics$129.01M$19.57M
ETONEton Pharmaceuticals$31.64M$10.32M
GNFTGenfit$28.57M$17.08M
HOWLWerewolf Therapeutics$19.94M$1.14M
TARSTarsus Pharmaceuticals$17.45M$48.12M
IKNAIkena Oncology$9.16M-
STOKStoke Therapeutics$8.78M$4.89M
CNTACentessa Pharmaceuticals$6.88M-
OPTOpthea$108.41K$61.27K
DSGNDesign Therapeutics--
ALDXAldeyra Therapeutics--
NUVLNuvalent--
PHVSPharvaris--
RLYBRallybio-$299.00K
CNTBConnect Biopharma--
ABOSAcumen Pharmaceuticals--
GLUEMonte Rosa Therapeutics-$4.70M
NUVBNuvation Bio-$727.00K
PEPGPepGen--
TYRATyra Biosciences--
ELDNEledon Pharmaceuticals--

TARS Revenue FAQ

What is Tarsus Pharmaceuticals’s yearly revenue?

Tarsus Pharmaceuticals's yearly revenue for 2023 was $17.45M, representing a decrease of -32.42% compared to 2022. The company's yearly revenue for 2022 was $25.82M, representing a decrease of -54.73% compared to 2021. TARS's yearly revenue for 2021 was $57.03M, representing an increase of 100.00% compared to 2020.

What is Tarsus Pharmaceuticals’s quarterly revenue?

Tarsus Pharmaceuticals's quarterly revenue for Q3 2024 was $48.12M, a 17.90% increase from the previous quarter (Q2 2024), and a 2471.78% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $40.81M, a 47.80% increase from the previous quarter (Q1 2024), and a 167.15% increase year-over-year (Q2 2023). TARS's quarterly revenue for Q1 2024 was $27.61M, a 111.18% increase from the previous quarter (Q4 2023), and a 1004.56% increase year-over-year (Q1 2023).

What is Tarsus Pharmaceuticals’s revenue growth rate?

Tarsus Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -69.41%, and for the last 5 years (2019-2023) was 0%.

What are Tarsus Pharmaceuticals’s revenue streams?

Tarsus Pharmaceuticals's revenue streams in c 23 are License Fees and Collaboration, and Product. License Fees and Collaboration generated $2.72M in revenue, accounting 15.58% of the company's total revenue, up 184.61% year-over-year. Product generated $14.73M in revenue, accounting 84.42% of the company's total revenue

What is Tarsus Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Tarsus Pharmaceuticals was Product. This segment made a revenue of $14.73M, representing 84.42% of the company's total revenue.